Home U.S. approves GSK’s ViiV Healthcare’s new HIV treatment

U.S. approves GSK’s ViiV Healthcare’s new HIV treatment

Share
Share

United States (U.S.) HIV specialist pharmaceutical company, ViiV Healthcare on Wednesday said that the U.S. Food and Drug Administration (FDA) has approved Cabenuva cabotegravir and rilpivirine for every two month dosing for the treatment of HIV-1.

The treatment is for HIV in virologically suppressed adults on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.

ViiV Healthcare is majority-owned by GlaxoSmithKline plc, with Pfizer and Shionogi Limited as shareholders.

Cabenuva is the first and only complete long-acting HIV treatment regimen and was first approved by the U.S. FDA in January 2021 as a once-monthly treatment for HIV-1 in virologic ally suppressed adults.

The U.S. FDA approval allows Cabenuva to be dosed monthly or every two months.

Long-acting cabotegravir and rilpivirine are approved for use every two months in Canada under the name Cabenuva and in the European Union (EU) as Vocabria and Rekambys.

(Quick News Africa)

 

Cover Photo Credit: Global Cosmetics News

Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

‎Building trust in Nigerian automotive marketplaces through better product design

‎By Emmanuel Idoko ‎‎An online car enquiry sets several processes in motion....

Governance & Global Affairs

Blind Nigerians still struggle to vote independently despite INEC’s Braille ballot promises

Abubakar Abdulrasheed The last time Anowo Victor could see the world around...

Faith & Inspiration

RCCG Family Week: Pastor Odutola urges accessible parenting

· ‎Confiance News witnessed a Pastor in Charge warn Nigerian parents that...

Business & Economy

‎FMDQ Group honours 25 winners at 2026 GOLD Awards‎

· ‎FMDQ Group has crowned 25 winners at its 9th GOLD Awards,...